Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6PXP3
UPID:
GTR7_HUMAN
Alternative names:
Glucose transporter type 7
Alternative UPACC:
Q6PXP3; A2A333
Background:
Solute carrier family 2, facilitated glucose transporter member 7, also known as Glucose transporter type 7, plays a crucial role in cellular metabolism by facilitating the transport of glucose and fructose. Despite ongoing debates regarding its physiological substrate, its ability to transport these sugars without handling galactose, 2-deoxy-d-glucose, and xylose is well-documented.
Therapeutic significance:
Understanding the role of Solute carrier family 2, facilitated glucose transporter member 7 could open doors to potential therapeutic strategies.